PPCB · Propanc Biopharma, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.”View the 10-Q filed May 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on May 18, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on May 18, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PPCB
this stock
Propanc Biopharma, Inc.
|
$3.08M | — | — | — | 2.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 2.1%
- Net QoQ
- +29.4K sh
- Top holder
- JANE STREET GROUP, LLC
Performance
Raw-price comparisons begin at the captured split on May 18, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PPCB | +25.0% | +33.7% | — | +33.7% | — |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +24.5% | +30.7% | — | +30.7% | — |